Report states that DecisionDx®-Melanoma offers more utility than other existing GEP assays or nomograms, supported by extensive evidence-driven data for the test in current literature Report includes 10 additional usage guidelines and consensus supporting statements for incorporating GEP testing, including DecisionDx-Melanoma, into clinical practice to improve care for patients with cutaneous melanoma FRIENDSWOOD, Texas–(BUSINESS WIRE)–$CSTL … [Read more…]

– Experienced Business and Financial Leader, Kellogg Served as Chief Financial Officer at Biogen, Merck, and Celgene – CAMBRIDGE, Mass.–(BUSINESS WIRE)–Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) the leading RNAi therapeutics company, announced today the appointment of Peter Kellogg to its Board of Directors. Mr. Kellogg is an accomplished industry executive with extensive global financial and strategic … [Read more…]

Prof. Dr. Pieter Reitsma, former CSO and founder, to continue as Special Advisor to VarmX management & Board LEIDEN, The Netherlands–(BUSINESS WIRE)–VarmX, a biotech company focusing on the development of innovative approaches for the reversal of anticoagulation, today announces the appointment of Dr. Jeffrey Lawson as its new Chief Scientific Officer (CSO). Dr. Lawson will … [Read more…]

Diversey Public Shareholders to Receive $8.40 Per Share in Cash in “Go Private” Transaction Combined company will allow for expanded markets and additional sustainable solutions WILMINGTON, Del. & FORT MILL, S.C.–(BUSINESS WIRE)–Solenis (“Solenis”) and Diversey Holdings, Ltd. (“Diversey” or the “Company”) (NASDAQ: DSEY) today announced they have entered into a definitive merger agreement under which … [Read more…]

RAHWAY, N.J.–(BUSINESS WIRE)–$MRK #MRK–Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Jannie Oosthuizen, president, Human Health U.S., is scheduled to participate in a fireside chat at the Barclays 2023 Global Healthcare Conference on Wednesday, March 15, 2023, at 2:35 p.m. ET. Investors, analysts, members of the media … [Read more…]

Achieved fourth quarter net product revenue of $32.5M representing 52% growth compared to Q4 2021 Achieved full-year net product revenue of $109.3M representing 38% annual growth compared to 2021 on a pro forma basis Ended 2022 with $122.0M in cash, cash equivalents, and short-term investments realizing $50M in synergies in 2022 from the Strongbridge acquisition … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Global ENT & Bronchoscopy Devices Market Size, Share, & COVID-19 Impact Analysis 2023-2029 – MedSuite – Includes: ENT Endoscopes, ENT Powered Instruments, and 9 more” report has been added to ResearchAndMarkets.com’s offering. In 2022, the global market for ENT endoscopic and bronchoscopic devices was valued at $6.8 billion. It is expected to grow … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “In Situ Hybridization Market Size, Share & Trends Analysis Report By Technology, By Probe, By Product, By Application, By End-use, By Region, And Segment Forecasts, 2023 – 2030” report has been added to ResearchAndMarkets.com’s offering. The global in situ hybridization market size is expected to reach USD 2.42 billion by 2030 and is … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Sepsis – Pipeline Insight, 2022” clinical trials has been added to ResearchAndMarkets.com’s offering. This “Sepsis- Pipeline Insight, 2022” report provides comprehensive insights about 40+ companies and 40+ pipeline drugs in Sepsis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product … [Read more…]

TOKYO–(BUSINESS WIRE)–Sumitomo Heavy Industries, Ltd. (“SHI”) (TOKYO:6302) (Head Office: Shinagawa-ku, Tokyo, President and CEO: Shinji Shimomura) announced the decision to invest in Alpha Fusion Inc. (“AF”) (Head Office: Kita-ku, Osaka, Chief Executive Officer: Sunao Fujioka), a developer of Astatine based radiopharmaceuticals for Targeted Alpha Therapy (“TAT”). AF will aim at establishing their pipeline (*1). Development … [Read more…]